ABSTRACT
Research on germline genetic variants relies on a sufficient number of eligible participants which is difficult to achieve for rare diseases such as childhood cancer. With self-collection kits using saliva or buccal swabs, participants can contribute genetic samples conveniently from their home. We identified determinants of participation in DNA self-collection in this cross-sectional study.
We invited 928 childhood cancer survivors in Switzerland with a median age of 26.5 years (interquartile range 18.8-36.5), of which 463 (50%) participated. Foreign nationality (odds ratio [OR] 0.5, 95%-confidence interval [CI] 0.4-0.7), survivors aged 30-39 years at study versus other age groups (OR 0.5, CI 0.4-0.8), and those with a known cancer predisposition syndrome (OR 0.5, CI 0.3-1.0) participated less. Survivors with a second primary neoplasm (OR 1.9, CI 1.0-3.8) or those living in a French or Italian speaking region (OR 1.3, 1.0-1.8) tended to participate more.
We showed that half of survivors participate in germline DNA self-sampling relying completely on mailing of sample kits. Foreign nationality, age 30-39 years, and cancer predisposition syndromes were associated with less participation. More targeted recruitment strategies may be advocated for these subgroups. To increase participation in DNA self-sampling, understanding and perceptions of survivors need to be better understood.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04702321
Funding Statement
This study is supported by the CANSEARCH Foundation for BISKIDS, the host biobank BaHOP, the research study GECCOS, and salary support to Nicolas Waespe and Sven Strebel. Further funding comes from the Swiss National Science Foundation (31BL30_185396), and Swiss Cancer Research (KFS-4722-02-2019, KLS/KFS-4825-01-2019). The funding bodies have no role in the design of the study and collection, analysis, and interpretation of data and in writing this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Geneva Cantonal Commission for Research Ethics has approved the BaHOP biobank (approval PB_2017-00533) and the Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study, which will utilize the samples (approval 2020-01723).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Datasets are available from the corresponding author on reasonable request for specific projects.
Abbreviations table
- BaHOP
- Biobank for Hematology and Oncology in Pediatrics
- BISKIDS
- Germline DNA Biobank Switzerland for Childhood Cancer and Blood Disorders
- CCS
- Childhood cancer survivor
- CNS
- Central nervous system
- CPS
- Cancer predisposition syndrome
- DNA
- Deoxyribonucleic acid
- GECCOS
- Genetic risks for childhood cancer complications Switzerland
- HSCT
- Hematopoietic stem cell transplantation
- ICCC-3
- International Classification of Childhood Cancer, third edition
- ISPM
- Institute of Social and Preventive Medicine
- SCCR
- Swiss Childhood Cancer Registry
- SPN
- Second primary neoplasm
